USP – Advances in the clinical development of PI3K inhibitors

October 25, 2021USP

These results provide strong preclinical and translational evidence for iberdomide activity and its potential for clinical development in MM in combination with other agents, especially with bortezomib and daratumumab in RRMM

by euromed2016

These results provide strong preclinical and translational evidence for iberdomide activity and its potential for clinical development in MM in combination with other agents, especially…